Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism

Z. Rychtarcikova, S. Lettlova, V. Tomkova, V. Korenkova, L. Langerova, E. Simonova, P. Zjablovskaja, M. Alberich-Jorda, J. Neuzil, J. Truksa,

. 2017 ; 8 (4) : 6376-6398.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18010879

The importance of iron in the growth and progression of tumors has been widely documented. In this report, we show that tumor-initiating cells (TICs), represented by spheres derived from the MCF7 cell line, exhibit higher intracellular labile iron pool, mitochondrial iron accumulation and are more susceptible to iron chelation. TICs also show activation of the IRP/IRE system, leading to higher iron uptake and decrease in iron storage, suggesting that level of properly assembled cytosolic iron-sulfur clusters (FeS) is reduced. This finding is confirmed by lower enzymatic activity of aconitase and FeS cluster biogenesis enzymes, as well as lower levels of reduced glutathione, implying reduced FeS clusters synthesis/utilization in TICs. Importantly, we have identified specific gene signature related to iron metabolism consisting of genes regulating iron uptake, mitochondrial FeS cluster biogenesis and hypoxic response (ABCB10, ACO1, CYBRD1, EPAS1, GLRX5, HEPH, HFE, IREB2, QSOX1 and TFRC). Principal component analysis based on this signature is able to distinguish TICs from cancer cells in vitro and also Leukemia-initiating cells (LICs) from non-LICs in the mouse model of acute promyelocytic leukemia (APL). Majority of the described changes were also recapitulated in an alternative model represented by MCF7 cells resistant to tamoxifen (TAMR) that exhibit features of TICs. Our findings point to the critical importance of redox balance and iron metabolism-related genes and proteins in the context of cancer and TICs that could be potentially used for cancer diagnostics or therapy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010879
003      
CZ-PrNML
005      
20180404142352.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.14093 $2 doi
035    __
$a (PubMed)28031527
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Rychtarcikova, Zuzana $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic. Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Hradec Kralove, Czech Republic.
245    10
$a Tumor-initiating cells of breast and prostate origin show alterations in the expression of genes related to iron metabolism / $c Z. Rychtarcikova, S. Lettlova, V. Tomkova, V. Korenkova, L. Langerova, E. Simonova, P. Zjablovskaja, M. Alberich-Jorda, J. Neuzil, J. Truksa,
520    9_
$a The importance of iron in the growth and progression of tumors has been widely documented. In this report, we show that tumor-initiating cells (TICs), represented by spheres derived from the MCF7 cell line, exhibit higher intracellular labile iron pool, mitochondrial iron accumulation and are more susceptible to iron chelation. TICs also show activation of the IRP/IRE system, leading to higher iron uptake and decrease in iron storage, suggesting that level of properly assembled cytosolic iron-sulfur clusters (FeS) is reduced. This finding is confirmed by lower enzymatic activity of aconitase and FeS cluster biogenesis enzymes, as well as lower levels of reduced glutathione, implying reduced FeS clusters synthesis/utilization in TICs. Importantly, we have identified specific gene signature related to iron metabolism consisting of genes regulating iron uptake, mitochondrial FeS cluster biogenesis and hypoxic response (ABCB10, ACO1, CYBRD1, EPAS1, GLRX5, HEPH, HFE, IREB2, QSOX1 and TFRC). Principal component analysis based on this signature is able to distinguish TICs from cancer cells in vitro and also Leukemia-initiating cells (LICs) from non-LICs in the mouse model of acute promyelocytic leukemia (APL). Majority of the described changes were also recapitulated in an alternative model represented by MCF7 cells resistant to tamoxifen (TAMR) that exhibit features of TICs. Our findings point to the critical importance of redox balance and iron metabolism-related genes and proteins in the context of cancer and TICs that could be potentially used for cancer diagnostics or therapy.
650    _2
$a zvířata $7 D000818
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a biologický transport $7 D001692
650    _2
$a nádory prsu $x farmakoterapie $x enzymologie $x genetika $x patologie $7 D001943
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a chemorezistence $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    _2
$a regulace genové exprese enzymů $7 D015971
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a železo $x metabolismus $7 D007501
650    _2
$a chelátory železa $x farmakologie $7 D007502
650    _2
$a akutní promyelocytární leukemie $x enzymologie $x genetika $7 D015473
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši transgenní $7 D008822
650    _2
$a mitochondrie $x enzymologie $7 D008928
650    _2
$a nádorové kmenové buňky $x účinky léků $x enzymologie $x patologie $7 D014411
650    _2
$a fenotyp $7 D010641
650    _2
$a analýza hlavních komponent $7 D025341
650    _2
$a nádory prostaty $x farmakoterapie $x enzymologie $x genetika $x patologie $7 D011471
650    _2
$a buněčné sféroidy $7 D018874
650    _2
$a tamoxifen $x farmakologie $7 D013629
650    12
$a transkriptom $7 D059467
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lettlova, Sandra $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic. Charles University in Prague, Faculty of Sciences, Prague, Czech Republic.
700    1_
$a Tomkova, Veronika $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic. Charles University in Prague, Faculty of Sciences, Prague, Czech Republic.
700    1_
$a Korenkova, Vlasta $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Langerova, Lucie $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Simonova, Ekaterina $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Zjablovskaja, Polina $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Alberich-Jorda, Meritxell $u Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Neuzil, Jiri $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic. School of Medical Science, Menzies Health Institute Queensland, Southport, Queensland, Australia.
700    1_
$a Truksa, Jaroslav $u Institute of Biotechnology, Czech Academy of Sciences, Prague, Czech Republic.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 4 (2017), s. 6376-6398
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28031527 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180404142432 $b ABA008
999    __
$a ok $b bmc $g 1288364 $s 1007691
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 4 $d 6376-6398 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options